Back

AAV9-MCT8 delivery at juvenile stage ameliorates neurological and behavioral deficits in an AHDS mouse model

Liao, X.-H.; Avalos, P.; Oksana, S.; Ofan, R.; Shilo, M.; Bresee, C.; Likhite, S.; Vit, J.-P.; Heuer, H.; Kaspar, B.; Kathrin, M.; Dumitrescu, A. M.; Refetoff, S.; Svendsen, C. N.; Vatine, G. D.

2021-11-02 neuroscience
10.1101/2021.10.31.466634 bioRxiv
Show abstract

Allan-Herndon-Dudley syndrome (AHDS) is a severe X-linked intellectual and psychomotor disability disorder accompanied by abnormal thyroid hormone (TH) levels. AHDS is caused by inactivating mutations in the monocarboxylate transporter 8 (MCT8), a specific TH transporter widely expressed in the central nervous system. MCT8 gene mutations cause impaired transport of TH across brain barriers, leading to insufficient neural TH supply. There is currently no successful therapy for the neurological symptoms. AAV9-based gene therapy is a promising approach to treat monogenic neurological disorders. Here, the potential of this approach was tested in the well-established double knockout (dKO) Mct8-/y;Oatp1c1-/- mouse model of AHDS, which displays disease-relevant neurological and TH phenotypes. Systemic intravenous delivery of AAV9-MCT8 at a juvenile stage led to improved locomotor and cognitive function, as well as rescue of T3-brain content and T3-related gene expression. This preclinical study indicates that this gene therapy may improve the neurological symptoms of AHDS patients.

Matching journals

The top 10 journals account for 50% of the predicted probability mass.

1
Scientific Reports
○ 3612 papers in training set
Top 3%
12.0%
Similar papers in this journal
2
Molecular Psychiatry
○ 282 papers in training set
Top 0.5%
11.1%
Similar papers in this journal
3
Nature Communications
○ 5641 papers in training set
Top 30%
4.3%
Similar papers in this journal
4
Molecular Therapy
○ 81 papers in training set
Top 0.4%
4.1%
Similar papers in this journal
5
iScience
○ 1154 papers in training set
Top 4%
4.1%
Similar papers in this journal
6
eLife
● 5828 papers in training set
Top 34%
3.3%
7
JCI Insight
● 277 papers in training set
Top 2%
3.2%
8
Human Molecular Genetics
◐ 141 papers in training set
Top 0.8%
3.2%
9
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
○ 26 papers in training set
Top 0.1%
3.2%
10
Neurobiology of Disease
○ 148 papers in training set
Top 1%
3.2%
50% of probability mass above
11
Molecular Therapy Nucleic Acids
○ 39 papers in training set
Top 0.3%
2.7%
12
Experimental Neurology
○ 61 papers in training set
Top 0.5%
2.1%
13
Annals of Neurology
○ 64 papers in training set
Top 0.8%
2.1%
14
Frontiers in Neuroscience
○ 256 papers in training set
Top 2%
2.1%
15
Brain
◐ 168 papers in training set
Top 2%
1.9%
16
The American Journal of Pathology
○ 32 papers in training set
Top 0.4%
1.7%
17
Biomedicine & Pharmacotherapy
○ 42 papers in training set
Top 0.7%
1.5%
18
International Journal of Molecular Sciences
○ 494 papers in training set
Top 9%
1.5%
19
The Journal of Neuroscience
● 1025 papers in training set
Top 8%
1.4%
20
Neurotherapeutics
○ 14 papers in training set
Top 0.1%
1.3%
21
Molecular Therapy - Methods & Clinical Development
○ 38 papers in training set
Top 0.4%
1.3%
22
Translational Psychiatry
○ 260 papers in training set
Top 3%
1.1%
23
Molecular Therapy Methods & Clinical Development
○ 13 papers in training set
Top 0.1%
1.1%
24
Disease Models & Mechanisms
139 papers in training set
Top 2%
1.1%
25
Communications Biology
○ 993 papers in training set
Top 25%
1.0%
26
Fluids and Barriers of the CNS
○ 28 papers in training set
Top 0.4%
1.0%
27
Pediatric Research
○ 21 papers in training set
Top 0.4%
0.9%
28
Brain Communications
◐ 166 papers in training set
Top 3%
0.8%
29
PLOS ONE
● 5266 papers in training set
Top 58%
0.8%
30
Cell Death & Disease
147 papers in training set
Top 4%
0.6%

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.